Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Sichuan Kelun-Biotech has amended its Auxiliary R&D Services Framework Agreement to include new service scopes and revised pricing policies, ensuring all transactions with Kelun Pharmaceutical remain on normal commercial terms. These revisions affect the annual caps for 2024 and 2025, but the overall agreement terms remain largely unchanged. Significant company directors with a vested interest abstained from the revision approval votes to avoid conflict of interest.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.